{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T06:33:22Z","timestamp":1777358002618,"version":"3.51.4"},"reference-count":151,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Hereditary cancer syndromes, including pathogenic variants in\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      and mismatch-repair genes, confer a substantial risk of several malignancies, including ovarian, endometrial, and fallopian tube cancers. Given the limited efficacy of current screening strategies, particularly for ovarian cancer, a prevention-focused approach is required. This review synthesizes evidence on identification, risk stratification, surveillance, chemoprevention, and prophylactic surgery in women with inherited gynecologic cancer susceptibility, proposing a precision-prevention framework.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A structured search of MEDLINE, Embase, and the Cochrane Library was conducted through July 2025. Original studies, reviews, and guidelines in English were included following independent screening and full-text assessment by two authors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Expanded germline testing, universal mismatch-repair screening, and genomic profiling have improved carrier identification beyond family history\u2013based criteria. Integrated counseling models enhance informed decision-making and access to care. Conventional surveillance tools show limited sensitivity; emerging strategies, including circulating tumor DNA assays and artificial intelligence, require further validation. Hormonal and anti-inflammatory agents demonstrate potential for risk reduction. Prophylactic surgery, including salpingo-oophorectomy, hysterectomy, or investigational salpingectomy with delayed oophorectomy, remains central, requiring multidisciplinary evaluation and attention to fertility, menopausal health, and patient preferences. Ethical and health-economic considerations remain critical in clinical practice and policy development. Further studies are warranted to better elucidate the potential role of liquid biopsy, microbiota, and targeted vaccination strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Prevention of gynecologic cancers in genetically predisposed women requires an integrated strategy that includes comprehensive genetic assessment, risk-adapted surveillance, evidence-based risk-reduction interventions, and multidisciplinary coordination. Implementing and refining precision prevention frameworks is crucial to optimize outcomes and translate genetic risk into tailored preventive care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1811964","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T05:35:23Z","timestamp":1777354523000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Hereditary cancer syndromes with gynecological cancer risk: focus on prevention strategies"],"prefix":"10.3389","volume":"16","author":[{"given":"Simona","family":"Duranti","sequence":"first","affiliation":[{"name":"Scientific Directorate, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Iacobelli","sequence":"additional","affiliation":[{"name":"Unit of Oncological Gynecology, Women\u2019s Children\u2019s and Public Health Department, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS","place":["Rome, Italy"]},{"name":"Universit\u00e0 Cattolica del Sacro Cuore","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Trozzi","sequence":"additional","affiliation":[{"name":"Unit of Oncological Gynecology, Women\u2019s Children\u2019s and Public Health Department, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS","place":["Rome, Italy"]},{"name":"Universit\u00e0 Cattolica del Sacro Cuore","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Floriana","family":"Camarda","sequence":"additional","affiliation":[{"name":"Unit of Oncological Gynecology, Women\u2019s Children\u2019s and Public Health Department, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS","place":["Rome, Italy"]},{"name":"Universit\u00e0 Cattolica del Sacro Cuore","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arianna","family":"Panfili","sequence":"additional","affiliation":[{"name":"UOC Genetica Medica, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Fagotti","sequence":"additional","affiliation":[{"name":"Unit of Oncological Gynecology, Women\u2019s Children\u2019s and Public Health Department, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS","place":["Rome, Italy"]},{"name":"Universit\u00e0 Cattolica del Sacro Cuore","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Fanfani","sequence":"additional","affiliation":[{"name":"Unit of Oncological Gynecology, Women\u2019s Children\u2019s and Public Health Department, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS","place":["Rome, Italy"]},{"name":"Universit\u00e0 Cattolica del Sacro Cuore","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Marchetti","sequence":"additional","affiliation":[{"name":"Unit of Oncological Gynecology, Women\u2019s Children\u2019s and Public Health Department, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS","place":["Rome, Italy"]},{"name":"Universit\u00e0 Cattolica del Sacro Cuore","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla","family":"Nero","sequence":"additional","affiliation":[{"name":"Unit of Oncological Gynecology, Women\u2019s Children\u2019s and Public Health Department, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS","place":["Rome, Italy"]},{"name":"Universit\u00e0 Cattolica del Sacro Cuore","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"B1","volume-title":"NCCN clinical practice guidelines in oncology: Genetic\/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate (Version 1.2026)","year":"2026"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-314057","article-title":"Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database","volume":"67","author":"M\u00f8ller","year":"2018","journal-title":"Gut"},{"key":"B3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41436-019-0596-9","article-title":"Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database","volume":"22","author":"Dominguez-Valentin","year":"2020","journal-title":"Genet Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA-a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge","year":"2019","journal-title":"Res Integr Peer Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.16372","article-title":"Pathogenic germline variants in cancer susceptibility genes","volume":"334","author":"Idumah","year":"2025","journal-title":"JAMA"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.1066","article-title":"Meta-analysis of BRCA1 and BRCA2 penetrance","volume":"25","author":"Chen","year":"2007","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.2820","article-title":"Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation","volume":"32","author":"Finch","year":"2014","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkaa029","article-title":"Penetrance of breast and ovarian cancer in women who carry a BRCA1\/2 mutation and do not use risk-reducing salpingo-oophorectomy: an updated meta-analysis","volume":"4","author":"Chen","year":"2020","journal-title":"JNCI Cancer Spectr"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.131","article-title":"Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations","volume":"21","author":"Levine","year":"2003","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02112","article-title":"Cancer risks associated with BRCA1 and BRCA2 pathogenic variants","volume":"40","author":"Li","year":"2022","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmig.2020.11.023","article-title":"Endometrial cancer in germline BRCA mutation carriers: A systematic review and meta-analysis","volume":"28","author":"Matanes","year":"2021","journal-title":"J Minim Invasive Gynecol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-020-05887-7","article-title":"Association between BRCA mutations and endometrial carcinoma: a systematic review with meta-analysis","volume":"303","author":"Lu","year":"2021","journal-title":"Arch Gynecol Obstet"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt095","article-title":"Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE","volume":"105","author":"Mavaddat","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"B15","article-title":"Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations","volume":"60","author":"Lal","year":"2000","journal-title":"Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1822","article-title":"Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations","volume":"15","author":"Agalliu","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.eururo.2019.08.025","article-title":"Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers: A prospective cohort study","volume":"77","author":"Nyberg","year":"2020","journal-title":"Eur Urol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S1470-2045(10)70265-5","article-title":"Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study","volume":"12","author":"Kempers","year":"2011","journal-title":"Lancet Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.743","article-title":"Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome","volume":"305","author":"Bonadona","year":"2011","journal-title":"JAMA"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-309675","article-title":"Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database","volume":"66","author":"M\u00f8ller","year":"2017","journal-title":"Gut"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-012-9591-x","article-title":"EPCAM deletion carriers constitute a unique subgroup of Lynch syndrome patients","volume":"12","author":"Ligtenberg","year":"2013","journal-title":"Fam Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.08.030","article-title":"Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls","volume":"147","author":"Lilyquist","year":"2017","journal-title":"Gynecol Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.16.00066","article-title":"Breast and ovarian cancer penetrance estimates derived from germline multiple-gene sequencing results in women","volume":"1","author":"Kurian","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.5495","article-title":"Inherited mutations in women with ovarian carcinoma","volume":"2","author":"Norquist","year":"2016","journal-title":"JAMA Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01907","article-title":"Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families","volume":"38","author":"Yang","year":"2020","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13058-018-0935-9","article-title":"BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer","volume":"20","author":"Weber-Lassalle","year":"2018","journal-title":"Breast Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040849","article-title":"Recurrent mutations in BRCA1, BRCA2, RAD51C, PALB2 and CHEK2 in polish patients with ovarian cancer","volume":"13","author":"\u0141ukomska","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2019-106739","article-title":"Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer","volume":"58","author":"Song","year":"2021","journal-title":"J Med Genet"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.2408","article-title":"Contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population","volume":"33","author":"Song","year":"2015","journal-title":"J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/jnci\/djac188","article-title":"Cancer risks by sex and variant type in PTEN hamartoma tumor syndrome","volume":"115","author":"Hendricks","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2283","article-title":"Lifetime cancer risks in individuals with germline PTEN mutations","volume":"18","author":"Tan","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0083","article-title":"Frequency and spectrum of cancers in the Peutz-Jeghers syndrome","volume":"12","author":"Hearle","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2000.20228","article-title":"Very high risk of cancer in familial Peutz-Jeghers syndrome","volume":"119","author":"Giardiello","year":"2000","journal-title":"Gastroenterology"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1160","article-title":"The impact of li-fraumeni and germline retinoblastoma mutations on leiomyosarcoma initiation, outcomes, and genetic testing recommendations","volume":"30","author":"Dermawan","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-018-00116-2","article-title":"Multi-gene panel testing confirms phenotypic variability in MUTYH-Associated Polyposis","volume":"18","author":"Sutcliffe","year":"2019","journal-title":"Fam Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2008.09.022","article-title":"Endometrial cancer and somatic G>T KRAS transversion in patients with constitutional MUTYH biallelic mutations","volume":"274","author":"Tricarico","year":"2009","journal-title":"Cancer Lett"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-020-0922-2","article-title":"Role of POLE and POLD1 in familial cancer","volume":"22","author":"Mur","year":"2020","journal-title":"Genet Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3089","article-title":"DICER1 and associated conditions: identification of at-risk individuals and recommended surveillance strategies","volume":"24","author":"Schultz","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a036541","article-title":"Cancer genetic counseling-current practice and future challenges","volume":"10","author":"Schienda","year":"2020","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1097\/CEJ.0000000000000677","article-title":"Universal testing for MSI\/MMR status in colorectal and endometrial cancers to identify Lynch syndrome cases: state of the art in Italy and consensus recommendations from the Italian Association for the Study of Familial Gastrointestinal Tumors (A.I.F.E.G.)","volume":"31","author":"Tibiletti","year":"2022","journal-title":"Eur J Cancer Prev"},{"key":"B41","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group","volume":"35","author":"Mosele","year":"2024","journal-title":"Ann Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.12.003","article-title":"Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations","volume":"34","author":"Kuzbari","year":"2023","journal-title":"Ann Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12101746","article-title":"Integrating a comprehensive cancer genome profiling into clinical practice: A blueprint in an italian referral center","volume":"12","author":"Nero","year":"2022","journal-title":"J Pers Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1093\/humupd\/dmab007","article-title":"The role of preimplantation genetic testing for hereditary cancer predisposition syndromes","volume":"27","author":"Harper","year":"2021","journal-title":"Hum Reprod Update"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3390\/genes14112069","article-title":"Public awareness and acceptability of PGT-M in cancer predisposition syndromes","volume":"14","author":"Calosci","year":"2023","journal-title":"Genes (Basel)"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2024.101270","article-title":"Ethical, legal, and social issues related to genetics and genomics in cancer: A scoping review and narrative synthesis","volume":"26","author":"Smit","year":"2024","journal-title":"Genet Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare13080880","article-title":"Ethical and psychosocial issues associated with genetic testing for hereditary tumor predisposition syndromes","volume":"13","author":"Hachmeriyan","year":"2025","journal-title":"Healthcare (Basel)"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3968","article-title":"Randomized study of remote telehealth genetic services versus usual care in oncology practices without genetic counselors","volume":"10","author":"Cacioppo","year":"2021","journal-title":"Cancer Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/cge.14660","article-title":"Mainstreaming cancer genomic testing: A scoping review of the acceptability, efficacy, and impact","volume":"107","author":"Berkman","year":"2025","journal-title":"Clin Genet"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040925","article-title":"Interventions facilitating family communication of genetic testing results and cascade screening in hereditary breast\/ovarian cancer or Lynch syndrome: A systematic review and meta-analysis","volume":"13","author":"Baroutsou","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B52","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13058-025-02081-y","article-title":"The impact of a mainstream genetic testing pathway and socioeconomic factors on the uptake of germline genetic testing in breast cancer patients: results of the nationwide GENE-SMART study","volume":"27","author":"Jong","year":"2025","journal-title":"Breast Cancer Res"},{"key":"B53","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s44276-024-00099-x","article-title":"Commentary: Why is genetic testing underutilized worldwide? The case for hereditary breast cancer","volume":"2","author":"Pederson","year":"2024","journal-title":"BJC Rep"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1380349","article-title":"MAGENTA: a multinational patient survey assessing the awareness, perceptions and unmet needs in genetic testing and counselling among patients with breast cancer","volume":"14","author":"Powell","year":"2024","journal-title":"Front Oncol"},{"key":"B55","volume-title":"NCCN clinical practice guidelines in oncology: Genetic\/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric (Version 1.2025)","year":"2026"},{"key":"B56","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.annonc.2022.10.004","article-title":"Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO clinical practice guideline","volume":"34","author":"Sessa","year":"2023","journal-title":"Ann Oncol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/GIM.0b013e31815f524f","article-title":"A systematic review of perceived risks, psychological and behavioral impacts of genetic testing","volume":"10","author":"Heshka","year":"2008","journal-title":"Genet Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djh017","article-title":"Psychological impact of genetic counseling for familial cancer: a systematic review and meta-analysis","volume":"96","author":"Braithwaite","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12121943","article-title":"Investigating psychological impact after receiving genetic risk results-a survey of participants in a population genomic screening program","volume":"12","author":"McCormick","year":"2022","journal-title":"J Pers Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1186\/s12910-020-0452-0","article-title":"Ethical values supporting the disclosure of incidental and secondary findings in clinical genomic testing: a qualitative study","volume":"21","author":"Saelaert","year":"2020","journal-title":"BMC Med Ethics"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ejhg.5201117","article-title":"Genetic information and testing in insurance and employment: technical, social and ethical issues","volume":"11","author":"Godard","year":"2003","journal-title":"Eur J Hum Genet"},{"key":"B62","volume-title":"Assessing Genetic Risks: Implications For Health And Social Policy","author":"Andrews","year":"1994"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25010204","article-title":"BRCA mutations and fertility preservation","volume":"25","author":"Dias Nunes","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0619","article-title":"Association of mismatch repair mutation with age at cancer onset in Lynch syndrome: Implications for stratified surveillance strategies","volume":"3","author":"Ryan","year":"2017","journal-title":"JAMA Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1093\/hropen\/hoac057","article-title":"ESGO\/ESHRE\/ESGE guidelines for the fertility-sparing treatment of patients with endometrial carcinoma","volume":"2023","author":"Rodolakis","year":"2023","journal-title":"Hum Reprod Open"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.6937","article-title":"Bilateral oophorectomy and all-cause mortality in women with BRCA1 and BRCA2 sequence variations","volume":"10","author":"Kotsopoulos","year":"2024","journal-title":"JAMA Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.9626","article-title":"Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study","volume":"26","author":"Kauff","year":"2008","journal-title":"J Clin Oncol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn442","article-title":"Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers","volume":"101","author":"Rebbeck","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1186\/s12905-014-0150-5","article-title":"Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers","volume":"14","author":"Marchetti","year":"2014","journal-title":"BMC Womens Health"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2022-003893","article-title":"Ovarian cancer onset across different BRCA mutation types: a view to a more tailored approach for BRCA mutated patients","volume":"33","author":"Marchetti","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020119","article-title":"Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation","volume":"346","author":"Kauff","year":"2002","journal-title":"N Engl J Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djae151","article-title":"Incidence of peritoneal cancer after oophorectomy among BRCA1 and BRCA2 mutation carriers","volume":"116","author":"Narod","year":"2024","journal-title":"J Natl Cancer Inst"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.17.1475","article-title":"Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers","volume":"91","author":"Rebbeck","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.7496","article-title":"Breast cancer risk after salpingo-oophorectomy in healthy BRCA1\/2 mutation carriers: a prospective cohort study","volume":"33","author":"Heemskerk-Gerritsen","year":"2015","journal-title":"J Clin Oncol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.24510","article-title":"Opportunistic salpingectomy for prevention of tubo-ovarian carcinoma: The European Society of Gynaecological Oncology consensus statements","volume":"335","author":"Piek","year":"2026","journal-title":"JAMA"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2023-004377","article-title":"TUBectomy with delayed oophorectomy as an alternative to risk-reducing salpingo-oophorectomy in high-risk women to assess the safety of prevention: the TUBA-WISP II study protocol","volume":"33","author":"Steenbeek","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2020-001541","article-title":"Preventing ovarian cancer through early excision of tubes and late ovarian removal (PROTECTOR): protocol for a prospective non-randomised multi-center trial","volume":"31","author":"Gaba","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS10615","article-title":"NRG-CC008: A nonrandomized prospective clinical trial comparing the non-inferiority of salpingectomy to salpingo-oophorectomy to reduce the risk of ovarian cancer among BRCA1 carriers (SOROCk)","volume":"40","author":"Huh","year":"2022","journal-title":"J Clin Oncol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2018.08.250","article-title":"Prophylactic hysterectomy in Lynch syndrome: feasibility and outcomes","volume":"234","author":"Pacelli","year":"2019","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051400","article-title":"Lynch syndrome and gynecologic tumors: incidence, prophylaxis, and management of patients with cancer","volume":"15","author":"Capasso","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2013.10.033","article-title":"Prevalence of occult gynecologic malignancy at the time of risk reducing and nonprophylactic surgery in patients with Lynch syndrome","volume":"132","author":"Lachiewicz","year":"2014","journal-title":"Gynecol Oncol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ygyno.2018.12.014","article-title":"Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits","volume":"153","author":"Gordhandas","year":"2019","journal-title":"Gynecol Oncol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2018.09.018","article-title":"Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis","volume":"132","author":"Marchetti","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-025-01298-5","article-title":"Updates in hormone replacement therapy for survivors of gynecologic cancers","volume":"26","author":"Gorman","year":"2025","journal-title":"Curr Treat Options Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.16896","article-title":"Risk-reducing salpingo-oophorectomy and the use of hormone replacement therapy below the age of natural menopause: Scientific Impact Paper No. 66 October 2021","volume":"129","author":"Manchanda","year":"2022","journal-title":"BJOG"},{"key":"B86","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/humupd\/dmac038","article-title":"Contraceptives and cancer risks in BRCA1\/2 pathogenic variant carriers: a systematic review and meta-analysis","volume":"29","author":"van Bommel","year":"2023","journal-title":"Hum Reprod Update"},{"key":"B87","doi-asserted-by":"publisher","first-page":"51.e1","DOI":"10.1016\/j.ajog.2021.01.014","article-title":"Oral contraceptive use and ovarian cancer risk for BRCA1\/2 mutation carriers: an international cohort study","volume":"225","author":"Schrijver","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djac004","article-title":"Oral contraceptive use in BRCA1 and BRCA2 mutation carriers: absolute cancer risks and benefits","volume":"114","author":"Schrijver","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1007\/s40495-018-0133-6","article-title":"The chemoprevention of ovarian cancer: the need and the options","volume":"4","author":"Kathawala","year":"2018","journal-title":"Curr Pharmacol Rep"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29386","article-title":"Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers","volume":"137","author":"Kotsopoulos","year":"2015","journal-title":"Int J Cancer"},{"key":"B91","article-title":"Oral contraception use in BRCA gene mutation carriers: information for counselling in routine clinical practice","volume":"42","author":"Cassani","year":"2021","journal-title":"Eur J Gynaecol Oncol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.04.018","article-title":"Oral contraceptive use and breast or ovarian cancer risk in BRCA1\/2 carriers: a meta-analysis","volume":"46","author":"Iodice","year":"2010","journal-title":"Eur J Cancer"},{"key":"B93","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1097\/aog.0000000000003463","article-title":"Intrauterine device use and ovarian cancer risk: a systematic review and meta-analysis","volume":"134","author":"Wheeler","year":"2019","journal-title":"Obstet Gynecol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1080\/01443615.2020.1789960","article-title":"Ever-use of the intra-uterine device and the risk of ovarian cancer","volume":"41","author":"Balayla","year":"2021","journal-title":"J Obstet Gynaecol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2018.02.006","article-title":"Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer. Results from the NOWAC study","volume":"149","author":"Jareid","year":"2018","journal-title":"Gynecol Oncol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1080\/0284186x.2016.1175660","article-title":"Impact of levonorgestrel-releasing intrauterine system use on the cancer risk of the ovary and fallopian tube","volume":"55","author":"Soini","year":"2016","journal-title":"Acta Oncol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"450.e1","DOI":"10.1016\/j.ajog.2024.05.011","article-title":"Association of levonorgestrel-releasing intrauterine device with gynecologic and breast cancers: a national cohort study in Sweden","volume":"231","author":"Yi","year":"2024","journal-title":"Am J Obstet Gynecol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1111\/aogs.13817","article-title":"Levonorgestrel-releasing intrauterine system and breast cancer risk: A systematic review and meta-analysis","volume":"99","author":"Conz","year":"2020","journal-title":"Acta Obstet Gynecol Scand"},{"key":"B99","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13053-022-00227-z","article-title":"Beyond the pill: contraception and the prevention of hereditary ovarian cancer","volume":"20","author":"Xia","year":"2022","journal-title":"Hered Cancer Clin Pract"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60167-1","article-title":"Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls","volume":"371","author":"Collaborative Group on Epidemiological Studies of Ovarian Cancer Beral","year":"2008","journal-title":"Lancet"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-024-00387-y","article-title":"Impact of hormonal contraception on endometrial histology in patients with Lynch syndrome, a retrospective pilot study","volume":"23","author":"Mawet","year":"2024","journal-title":"Fam Cancer"},{"key":"B102","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1001\/jama.2015.6789","article-title":"Female hormonal factors and the risk of endometrial cancer in Lynch syndrome","volume":"314","author":"Dashti","year":"2015","journal-title":"JAMA"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.20.1529","article-title":"Cyclooxygenase-2 inhibitors in tumorigenesis (part I)","volume":"90","author":"Taketo","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.21.1609","article-title":"Cyclooxygenase-2 inhibitors in tumorigenesis (part II)","volume":"90","author":"Taketo","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.101.10.1206","article-title":"Aspirin","volume":"101","author":"Awtry","year":"2000","journal-title":"Circulation"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-200007000-00001","article-title":"Beyond willow bark: aspirin in the prevention of chronic disease","volume":"11","author":"Thun","year":"2000","journal-title":"Epidemiology"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30366-4","article-title":"Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial","volume":"395","author":"Burn","year":"2020","journal-title":"Lancet"},{"key":"B108","unstructured":"Cancer Prevention Programme 3 (CaPP3)\n          \n          \n            \n              Burn\n              J"},{"key":"B109","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1001\/jama.294.1.47","article-title":"Low-dose aspirin in the primary prevention of cancer: the Women\u2019s Health Study: a randomized controlled trial","volume":"294","author":"Cook","year":"2005","journal-title":"JAMA"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(11)61720-0","article-title":"Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: Analysis of the time course of risks and benefits in 51 randomised controlled trials","volume":"379","author":"Rothwell","year":"2012","journal-title":"Lancet"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1111\/aogs.12069","article-title":"Nonsteroidal anti-inflammatory drugs and risk of ovarian cancer: systematic review and meta-analysis of observational studies","volume":"92","author":"Baandrup","year":"2013","journal-title":"Acta Obstet Gynecol Scand"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2016.04.543","article-title":"Is aspirin use associated with a decreased risk of ovarian cancer? A systematic review and meta-analysis of observational studies with dose-response analysis","volume":"142","author":"Zhang","year":"2016","journal-title":"Gynecol Oncol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01900","article-title":"Modification of the association between frequent aspirin use and ovarian cancer risk: A meta-analysis using individual-level data from two ovarian cancer consortia","volume":"40","author":"Hurwitz","year":"2022","journal-title":"J Clin Oncol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4156-5","article-title":"Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies","volume":"18","author":"Qiao","year":"2018","journal-title":"BMC Cancer"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt431","article-title":"Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: A pooled analysis in the Ovarian Cancer Association Consortium","volume":"106","author":"Trabert","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy100","article-title":"Analgesic use and ovarian cancer risk: An analysis in the Ovarian Cancer Cohort Consortium","volume":"111","author":"Trabert","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu578","article-title":"Low-dose aspirin use and the risk of ovarian cancer in Denmark","volume":"26","author":"Baandrup","year":"2015","journal-title":"Ann Oncol"},{"key":"B118","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1200\/jco.2011.39.7638","article-title":"Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule","volume":"31","author":"Rosenthal","year":"2013","journal-title":"J Clin Oncol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.9330","article-title":"Evidence of stage shift in women diagnosed with ovarian cancer during phase II of the United Kingdom Familial Ovarian Cancer Screening Study","volume":"35","author":"Rosenthal","year":"2017","journal-title":"J Clin Oncol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1186\/s13053-020-0137-1","article-title":"Diet, weight management, physical activity and Ovarian & Breast Cancer Risk in women with BRCA1\/2 pathogenic Germline gene variants: systematic review","volume":"18","author":"Coletta","year":"2020","journal-title":"Hered Cancer Clin Pract"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-017-4546-y","article-title":"Smoking and physical inactivity increase cancer prevalence in BRCA-1 and BRCA-2 mutation carriers: results from a retrospective observational analysis","volume":"296","author":"Grill","year":"2017","journal-title":"Arch Gynecol Obstet"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1007\/s10897-016-0049-4","article-title":"Lifestyle risk factors for breast cancer in BRCA1\/2-mutation carriers around childbearing age","volume":"26","author":"van Erkelens","year":"2017","journal-title":"J Genet Couns"},{"key":"B123","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1186\/s13063-016-1504-0","article-title":"Effects of lifestyle intervention in BRCA1\/2 mutation carriers on nutrition, BMI, and physical fitness (LIBRE study): study protocol for a randomized controlled trial","volume":"17","author":"Kiechle","year":"2016","journal-title":"Trials"},{"key":"B124","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s10689-019-00135-7","article-title":"Energy balance related lifestyle factors and risk of endometrial and colorectal cancer among individuals with lynch syndrome: a systematic review","volume":"18","author":"Coletta","year":"2019","journal-title":"Fam Cancer"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1007\/s10689-013-9645-8","article-title":"Do lifestyle factors influence colorectal cancer risk in Lynch syndrome","volume":"12","author":"van Duijnhoven","year":"2013","journal-title":"Fam Cancer"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13081849","article-title":"Body weight, physical activity, and risk of cancer in Lynch syndrome","volume":"13","author":"Siev\u00e4nen","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph192114098","article-title":"Lifestyle behavior interventions for preventing cancer in adults with inherited cancer syndromes: systematic review","volume":"19","author":"Diez de Los Rios de la Serna","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-22-0044","article-title":"Cancer prevention with resistant starch in Lynch syndrome patients in the CAPP2-randomized placebo controlled trial: Planned 10-year follow-up","volume":"15","author":"Mathers","year":"2022","journal-title":"Cancer Prev Res (Phila)"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1186\/s13053-024-00280-w","article-title":"Modifiable risk factors for cancer among people with lynch syndrome: an international, cross-sectional survey","volume":"22","author":"Power","year":"2024","journal-title":"Hered Cancer Clin Pract"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28758","article-title":"Considerations for the use of circulating tumor DNA sequencing as a screening tool in cancer predisposition syndromes","volume":"67","author":"Paramathas","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0456","article-title":"Early cancer detection in Li-Fraumeni syndrome with cell-free DNA","volume":"14","author":"Wong","year":"2024","journal-title":"Cancer Discov"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304714","article-title":"A cell-free DNA blood-based test for colorectal cancer screening","volume":"390","author":"Chung","year":"2024","journal-title":"N Engl J Med"},{"key":"B133","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.molmed.2020.12.011","article-title":"Liquid biopsy of methylation biomarkers in cell-free DNA","volume":"27","author":"Luo","year":"2021","journal-title":"Trends Mol Med"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.3390\/cells9030624","article-title":"DNA methylation-based testing in liquid biopsies as detection and prognostic biomarkers for the four major cancer types","volume":"9","author":"Const\u00e2ncio","year":"2020","journal-title":"Cells"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2023.08.014","article-title":"Current and new frontiers in hereditary cancer surveillance: Opportunities for liquid biopsy","volume":"110","author":"Farncombe","year":"2023","journal-title":"Am J Hum Genet"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.3390\/epigenomes6010006","article-title":"Opportunities for early cancer detection: The rise of ctDNA methylation-based pan-cancer screening technologies","volume":"6","author":"Constantin","year":"2022","journal-title":"Epigenomes"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04182-9","article-title":"Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b\/2 trial","volume":"32","author":"D\u2019Alise","year":"2026","journal-title":"Nat Med"},{"key":"B138","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13072-025-00595-5","article-title":"Artificial intelligence in cancer epigenomics: a review on advances in pan-cancer detection and precision medicine","volume":"18","author":"Sahoo","year":"2025","journal-title":"Epigenet Chromatin"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-025-01698-8","article-title":"Artificial intelligence and decision-making in oncology: A review of ethical, legal, and informed consent challenges","volume":"27","author":"Froicu","year":"2025","journal-title":"Curr Oncol Rep"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.08.018","article-title":"Racial disparity in gastrointestinal cancer risk","volume":"153","author":"Ashktorab","year":"2017","journal-title":"Gastroenterology"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.07.012","article-title":"Environmental factors, gut microbiota, and colorectal cancer prevention","volume":"17","author":"Song","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2020.05.013","article-title":"Microbiome in colorectal cancer: how to get from meta-omics to mechanism","volume":"28","author":"Ternes","year":"2020","journal-title":"Trends Microbiol"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-309595","article-title":"Tumour-associated and non-tumour-associated microbiota in colorectal cancer","volume":"66","author":"Flemer","year":"2017","journal-title":"Gut"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-025-03543-4","article-title":"Colorectal cancer in Lynch syndrome families: consequences of gene germline mutations and the gut microbiota","volume":"20","author":"Wang","year":"2025","journal-title":"Orphanet J Rare Dis"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2080-8","article-title":"Mutational signature in colorectal cancer caused by genotoxic pks+ E. coli","volume":"580","author":"Pleguezuelos-Manzano","year":"2020","journal-title":"Nature"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adi2556","article-title":"Genomic instability analysis in DNA from Papanicolaou test provides proof-of-principle early diagnosis of high-grade serous ovarian cancer","volume":"15","author":"Paracchini","year":"2023","journal-title":"Sci Transl Med"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.7566","article-title":"Detection of TP53 clonal variants in Papanicolaou test samples collected up to 6 years prior to high-grade serous epithelial ovarian cancer diagnosis","volume":"3","author":"Paracchini","year":"2020","journal-title":"JAMA Netw Open"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-019-0489-y","article-title":"The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome","volume":"21","author":"Crosbie","year":"2019","journal-title":"Genet Med"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30621","article-title":"Racial disparities in BRCA testing and cancer risk management across a population-based study of young breast cancer survivors","volume":"123","author":"Cragun","year":"2017","journal-title":"Cancer"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.02.011","article-title":"Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA","volume":"31","author":"Liu","year":"2020","journal-title":"Ann Oncol"},{"key":"B151","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41591-018-0300-7","article-title":"High-performance medicine: the convergence of human and artificial intelligence","volume":"25","author":"Topol","year":"2019","journal-title":"Nat Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1811964\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T05:35:33Z","timestamp":1777354533000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1811964\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":151,"alternative-id":["10.3389\/fonc.2026.1811964"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1811964","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"article-number":"1811964"}}